Top

Drugs & Aging

Published in:

19-03-2024 | Original Research Article

Older Canadians’ Perceptions of the Safety, Effectiveness and Accessibility of Cannabis for Medicinal Purposes: A Cross-Sectional Analysis

Authors: Jennifer Bolt, Jacob Movold, Megan Behm, Jill Williamson, Melanie Fenton, Jennifer M. Jakobi

Published in: Drugs & Aging | Issue 4/2024

Abstract

Background and Objective

Cannabis use is increasing among older adults, with use primarily for medicinal purposes. Much of the evidence on perceptions of cannabis is derived from younger populations and current users of cannabis. The purpose of this study was to describe community-dwelling older Canadians’ perceptions of cannabis effectiveness, safety and accessibility for medicinal purposes and to identify factors influencing cannabis perceptions.

Methods

An online survey of older adults’ perceptions, knowledge and experiences with cannabis was completed between February and September 2022. The survey was open to English-speaking and French-speaking Canadians aged 50 years and older regardless of their cannabis use history.

Results

A total of 1615 Canadians completed the survey. Respondents identified primarily as men (49.7%) or women (48.5%) of Caucasian decent. The majority of participants viewed cannabis as a reasonable alternative (65.8%) and an effective (70.5%) treatment modality for symptom management in older adults. Few respondents (16.4%) felt that older adults compared to younger adults were at a higher risk of side effects and 34.5% felt that cannabis is safe to use with most medicines. Cannabis perceptions were influenced by gender, cannabis use history (prior use vs current use) and reasons for cannabis use (recreational purposes vs medicinal purposes vs both purposes).

Conclusions

Older Canadians have a positive view of the role of cannabis in symptom management. The perceptions of cannabis safety and effectiveness were influenced by gender, cannabis use history and reasons for cannabis use. Healthcare professionals should leverage these perceptions when discussing cannabis with their older patient populations.

Statistics Canada. 2019. National cannabis survey, third quarter 2019. Available from: https://www150.statcan.gc.ca/n1/en/daily-quotidien/191030/dq191030a-eng.pdf?st=XAARmYVE. Accessed 21 Dec 2023.

Cox C. The Canadian Cannabis Act legalizes and regulates recreational cannabis use in 2018. Health Policy. 2018;122(3):205–9. https://doi.org/10.1016/j.healthpol.2018.01.009.CrossRefPubMed

Smith N, Stathokostas L, Clark P. Cannabis use and Canadian adults: a survey on use, interest and information needs. Active Aging Canada. 2020. Available from: https://www.activeagingcanada.ca/assets/pdf/practitioners/cannabis/Cannabis-Use-and-Canadian-Adults-Report.pdf. Accessed 5 Dec 2022.

Health Canada. Understanding the new access to cannabis for medical purposes regulations. Government of Canada. 2016. Available from: https://healthycanadians.gc.ca/publications/drugs-products-medicaments-produits/understanding-regulations-medical-cannabis-medicales-comprehension-reglements/index-eng.php. Accessed 21 Dec 2023.

Leos-Toro C, Shiplo S, Hammond D. Perceived support for medical cannabis use among approved medical cannabis users in Canada. Drug Alcohol Rev. 2018;37(5):627–36. https://doi.org/10.1111/dar.12823.CrossRefPubMed

Bobitt J, Clary K, Krawitz M, Silva LQ, Kang H. Prevention, practice and policy: older US veterans’ perspectives on cannabis use. Drugs Aging. 2023;40(1):59–70. https://doi.org/10.1007/s40266-022-00995-2.CrossRefPubMed

Johnston MC, Crilly M, Black C, Prescott GJ, Mercer SW. Defining and measuring multimorbidity: a systematic review of systematic reviews. Eur J Public Health. 2019;29(1):182–9. https://doi.org/10.1093/eurpub/cky098.CrossRefPubMed

Masnoon N, Shakib S, Kalisch-Ellet L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230. https://doi.org/10.1186/s12877-017-0621-2.CrossRefPubMedPubMedCentral

Tumati S, Lanctôt KL, Wang R, Li A, Davis A, Herrmann N. Medical cannabis use among older adults in Canada: self-reported data on types and amounts used, and perceived effects. Drugs Aging. 2022;39(2):153–63. https://doi.org/10.1007/s40266-021-00913-y.CrossRefPubMed

10.

Yang KH, Kaufmann CN, Nafsu R, Lifset E, Nguyen K, Sexton M, Han BH, Kim A, Moore AA. Cannabis: an emerging treatment for common symptoms in older adults. J Am Geriatr Soc. 2021;69(1):91–7. https://doi.org/10.1111/jgs.16833.CrossRefPubMed

11.

Reynolds IR, Fixen DR, Parnes BL, Lum HD, Shanbhag P, Church S, Linnebur SA, Orosz G. Characteristics and patterns of marijuana use in community-dwelling older adults. J Am Geriatr Soc. 2018;66(11):2167–71. https://doi.org/10.1111/jgs.15507.CrossRefPubMedPubMedCentral

12.

Manning L, Bouchard L. Medical cannabis use: exploring the perceptions and experiences of older adults with chronic conditions. Clin Gerontol. 2021;44(1):32–41. https://doi.org/10.1080/07317115.2020.1853299.CrossRefPubMed

13.

Spinella TC, Bartholomeusz J, Stewart SH, Barrett SP. Perceptions about THC and CBD effects among adults with and without prior cannabis experience. Addict Behav. 2023;137:107508. https://doi.org/10.1016/j.addbeh.2022.107508.CrossRefPubMed

14.

Turna J, Balodis I, Munn C, Van Ameringen M, Busse J, MacKillop J. Overlapping patterns of recreational and medical cannabis use in a large community sample of cannabis users. Compr Psychiatry. 2020;102:152188. https://doi.org/10.1016/j.comppsych.2020.152188.CrossRefPubMed

15.

Spackman E, Haines-Saah R, Danthurebandara VM, Dowsett LE, Noseworthy T, Clement FM. Marijuana use and perceptions of risk and harm: a survey among Canadians in 2016. Healthc Policy. 2017;13(1):17–27. https://doi.org/10.12927/hcpol.2017.25194.CrossRefPubMedPubMedCentral

16.

Heidari S, Babor TF, De Castro P, Tort S, Curno M. Sex and gender equity in research: rationale for the SAGER guidelines and recommended use. Res Integr Peer Rev. 2016;1:2. https://doi.org/10.1186/s41073-016-0007-6.CrossRefPubMedPubMedCentral

17.

Vlahiotis A, Sedjo R, Cox ER, Burroughs TE, Rauchway A, Lich R. Gender differences in self-reported symptom awareness and perceived ability to manage therapy with disease-modifying medication among commercially insured multiple sclerosis patients. J Manag Care Spec Pharm. 2010;16(3):206–16. https://doi.org/10.18553/jmcp.2010.16.3.206.CrossRef

18.

Watson S, Caster O, Rochon PA, den Ruijter H. Reported adverse drug reactions in women and men: aggregated evidence from globally collected individual case reports during half a century. EClinicalMedicine. 2019;17:100188. https://doi.org/10.1016/j.eclinm.2019.10.001.CrossRefPubMedPubMedCentral

19.

Zucker I, Prendergast BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol Sex Differ. 2020;11(1):32. https://doi.org/10.1186/s13293-020-00308-5.CrossRefPubMedPubMedCentral

20.

Soldin OP, Chung SH, Mattison DR. Sex differences in drug disposition. J Biomed Biotechnol. 2011;2011:187103. https://doi.org/10.1155/2011/187103.CrossRefPubMedPubMedCentral

21.

Aviram J, Lewitus GM, Vysotski Y, Berman P, Shapira A, Procaccia S, Meiri D. Sex difference in medical cannabis-related adverse effects. Pain. 2022;163(5):975–83. https://doi.org/10.1097/j.pain.0000000000002463.CrossRefPubMed

22.

Ng JY, Gilotra K, Usman S, Chang Y, Busse JW. Attitudes toward medical cannabis among family physicians practising in Ontario, Canada: a qualitative research study. CMAJ Open. 2021;9(2):E342–8. https://doi.org/10.9778/cmajo.20200187.CrossRefPubMedPubMedCentral

23.

Chandiok K, Marathe S, Rooney M, Stocker J, Tellis B, Pit S. Cannabis and its therapeutic value in the ageing population: attitudes of health-care providers. Australas J Ageing. 2021;40(3):261–74. https://doi.org/10.1111/ajag.12846.CrossRefPubMed

24.

Oldfield K, Braithwaite I, Beasley R, Eathorne A, Newton-Howes G, Semprini A. Medical cannabis: knowledge and expectations in a cohort of North Island New Zealand general practitioners. N Z Med J. 2020;133(1508):12–28.PubMed

25.

Bell LV, Fitzgerald SF, Flusk D, Poulin PA, Rash JA. Healthcare provider knowledge, beliefs, and attitudes regarding opioids for chronic non-cancer patient in North America prior to the emergency of COVID-19: a systematic review of qualitative research. Can J Pain. 2023;7(1):2156331. https://doi.org/10.1080/24740527.2022.2156331.CrossRefPubMedPubMedCentral

26.

Glose S, Arms T, Rowan N. Older adults’ knowledge, beliefs and attitudes about prescription opioids. Adv Dual Diagn. 2021;14(2):47–57. https://doi.org/10.1108/ADD-12-2020-0030.CrossRef

Title: Older Canadians’ Perceptions of the Safety, Effectiveness and Accessibility of Cannabis for Medicinal Purposes: A Cross-Sectional Analysis
Authors: Jennifer Bolt
Jacob Movold
Megan Behm
Jill Williamson
Melanie Fenton
Jennifer M. Jakobi
Publication date: 19-03-2024
Publisher: Springer International Publishing
Published in: Drugs & Aging / Issue 4/2024
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI: https://doi.org/10.1007/s40266-024-01109-w

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background and Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2024

Management of Scleritis in Older Adults

Cumulative Anticholinergic Burden and its Predictors among Older Adults with Alzheimer’s Disease Initiating Cholinesterase Inhibitors

Post-Stroke Depression in Older Adults: An Overview

Clinician and Family Caregiver Perspectives on Deprescribing Chronic Disease Medications in Older Nursing Home Residents Near the End of Life

The Effects of Pharmacological Urate-Lowering Therapy on Cardiovascular Disease in Older Adults with Gout

Patterns of Comorbidities and Prescribing and Dispensing of Non-steroidal Anti-inflammatory Drugs (NSAIDs) Among Patients with Osteoarthritis in the USA: Real-World Study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials